Tolerance to oral anticancer agent treatment in older adults with ...

Older adults were less likely to tolerate capecitabine treatment and had different co-occurring side effects compared to younger adults.

(PDF) Tolerance to oral anticancer agent treatment in older adults ...

Conclusions: Older adults were less likely to tolerate capecitabine treatment and had different co-occurring side effects compared to younger adults. While dose ...

More than 60% of cancer cases occur in older adults, and many are treated with oral anticancer agents. Yet, the treatment tolerability in older adults has ...

[PDF] Tolerance to oral anticancer agent treatment in older adults ...

Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of ...

(PDF) Tolerance to oral anticancer agent treatment in older adults ...

28%) than younger adults. Females, breast cancer diagnosis, capecitabine monotherapy, and severe HFS were found to be associated with dose reductions (ps<0.05).

Tolerance to oral anticancer agent treatment in older adults with ...

More than 60% of cancer cases occur in older adults, and many are treated with oral anticancer agents. Yet, the treatment tolerability in older adults has ...

Adherence to Oral Treatments in Older Patients with Advanced ...

Adherence to the prescription of oral anticancer treatments is underestimated and difficult to measure in oncology, although it may affect ...

Call to Action for Improving Oral Anticancer Agent Adherence

In a review of studies published between 2003 and 2015, adherence estimates for endocrine therapy and antineoplastic agents ranged from 46% to ...

Fatigue | Tolerance to oral anticancer agent treatment in older adults ...

The objective of this study was to investigate the tolerance of capecitabine, an example of oral chemotherapy, among older adults with cancer ...

Adherence to Targeted Oral Anticancer Medications - PMC

In 2008, it was estimated that 25–30% of the oncology drug pipeline involved oral agents, most of them targeted, with approximately 40% of all OAMs having been ...

Anticancer drugs are not well tolerated in all older patients with cancer

Studies on new anticancer drugs often inappropriately conclude that these treatments are well tolerated and feasible in the older population with cancer.

Tolerance of Toxicities of Oral Anticancer Agents among Older ...

Potentially, older patients may less tolerate OAA toxicities, which will impact the treatment effects and their quality of life. The overarching purpose is to ...

ASCO Awarded $11M to Study Oral Drug Dosing Strategies in Older ...

Older adults living with metastatic breast cancer are often unable to maintain full FDA-approved treatment doses of CDK4/6 inhibitors, with poor ...

Safety of solid oncology drugs in older patients: a narrative review

Understanding anticancer pharmacology and risks associated with age can prevent severe toxicities in older patients. Abstract. The older ...

Oral single-agent chemotherapy in older patients with solid tumours

Oral chemotherapy may be well suited to older patients with solid tumours. ... Implications for adherence must be considered. ... Oral capecitabine or vinorelbine ...

A Concept Analysis of Oral Anticancer Agent Self-management ...

Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of ...

Early follow-up of outpatients with oral anticancer therapy in the ...

Oral intake of OAT is effective, convenient, and preferred by patients,1 who can manage their treatment in an outpatient setting, enabling a ...

Observational study investigating Tolerance Of Anticancer Systemic ...

Methods and analysis Tolerance Of Anticancer Systemic Therapy In the Elderly is a prospective observational study of patients, aged ≥65 years, commencing first- ...

Preliminary secondary analyses from the Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer trial ...

Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy ...

Patients were 65 years and older with a solid malignant neoplasm, were starting a new chemotherapy regimen, and completed a geriatric assessment ...